Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long term safety and efficacy of Ustekinumab in refractory Crohn's disease patients

Trial Profile

Long term safety and efficacy of Ustekinumab in refractory Crohn's disease patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs Ustekinumab (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Jan 2018 Results of a study evaluating long term safety and efficacy and identifying the predictive factors of ustekinumab failure free persistence published in the Alimentary Pharmacology and Therapeutics
    • 08 Dec 2017 New trial record
    • 01 Nov 2017 Results presented at the 25th United European Gastroenterology Week
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top